Vedolizumab
Educational summary, not a formulary. Dosing is quoted from the Makindo chapters and topics site. The other sections are draft summaries not yet checked line by line against the BNF or SPC. Check dose, indication, interactions and monitoring in the BNF entry for Vedolizumab and local guidelines before prescribing.
Gut-selective biologic
Mechanism
Gut-selective alpha-4 beta-7 integrin antagonist.
Uses
Ulcerative colitis, Crohn disease.
Dosing
- Colitis | Diarrhoea, abdominal pain, blood. Exclude infection; steroids (prednisolone 1 mg/kg, or IV methylprednisolone if severe); infliximab or vedolizumab if no response in 48–72 hours
Oncology: Principles
Side effects
Infections, headache, arthralgia, infusion reactions.
Interactions
Avoid with natalizumab.
Contraindications and cautions
Active severe infection
Monitoring
Infection signs
Pregnancy and breastfeeding
Limited data
Renal and hepatic impairment
No adjustment
Overdose and reversal
Supportive
Special advice
Slow onset; check response at 14 weeks.
More from the textbook: uses, cautions and other points
- Vedolizumab | Alpha-4 beta-7 integrin (blocks white cells entering the gut only) | Gut-selective - fewer systemic infections; slower onset; useful in older people and those with infection risk
Gastroenterology: Anatomy Physiology Pharmacology - Vedolizumab / ustekinumab | Gut-selective integrin / IL-12/23 blockade.
Gastroenterology: Anatomy Physiology Pharmacology - Biologics (anti-TNF, ustekinumab, vedolizumab) under the IBD team.
Gastroenterology: Gastroenterology Emergencies (Complete) - Anti-TNF , vedolizumab and ustekinumab - usually continued throughout, sometimes with timing adjusted in the third trimester.
Gastroenterology: Inflammatory Bowel Disease - Immune checkpoint inhibitors (ipilimumab, nivolumab, pembrolizumab) - diarrhoea in cancer patients. Grade it, exclude infection, and give steroids early; infliximab or vedolizumab if refractory.
Gastroenterology: Inflammatory Bowel Disease - Vedolizumab | Gut-selective; low infection risk; UC and Crohn's.
Gastroenterology: Inflammatory Bowel Disease - Vedolizumab (anti-α4β7 integrin) - gut-selective - IBD - low systemic infection risk and no PML signal.
Clinical Immunology: Biologics, immunotherapy, checkpoint toxicity and transplant immunology - Colitis - infliximab or vedolizumab .
Clinical Immunology: Biologics, immunotherapy, checkpoint toxicity and transplant immunology
Where it is discussed in the book
- Gastroenterology: Anatomy Physiology Pharmacology (2 mentions)
- Gastroenterology: Gastroenterology Emergencies (Complete) (1 mention)
- Gastroenterology: Inflammatory Bowel Disease (3 mentions)
- Oncology: Principles (1 mention)
- Clinical Immunology: Biologics, immunotherapy, checkpoint toxicity and transplant immunology (3 mentions)